{
    "id": 1019,
    "fullName": "LOXL2 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type LOXL2 indicates that no mutation has been detected within the LOXL2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4017,
        "geneSymbol": "LOXL2",
        "terms": [
            "LOXL2",
            "LOR",
            "LOR2",
            "WS9-14"
        ]
    },
    "variant": "wild-type",
    "createDate": "07/17/2014",
    "updateDate": "03/20/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1303,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, the LOXL2 monoclonal antibody Simtuzumab (GS-6634) was well tolerated and, in combination with FOLFIRI, demonstrated potential efficacy against colon cancer (J Clin Oncol 32, 2014 (suppl 3; abstr 554)).",
            "molecularProfile": {
                "id": 1074,
                "profileName": "LOXL2 wild-type"
            },
            "therapy": {
                "id": 1704,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Simtuzumab",
                "synonyms": "Simtuzumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1009,
                    "pubMedId": null,
                    "title": "Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/123214-143"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1074,
            "profileName": "LOXL2 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}